Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis

作者：Lena Feber, Natalie Peter, Johannes Schneider‐Thoma, Spyridon Siafis, Irene Bighelli, Wulf‐Peter Hansen, Daniel Prates Baldez, Georgia Salanti, Richard S.E. Keefe, Rolf R. Engel, Stefan Leucht · 发表于：Systematic Reviews · 年份：2023 · DOI：10.1186/s13643-023-02213-5 · 被引用次数：22 · 研究领域：Meta-analysis and systematic reviews、Schizophrenia research and treatment、Treatment of Major Depression

BACKGROUND: There is evidence that antipsychotic drugs differ in their effect on the cognitive symptoms of schizophrenia. So far, there is no comprehensive systematic review available that would enable providers and patients to make informed choices regarding this important aspect of treatment. With a large number of substances available, conventional pairwise meta-analyses will not be sufficient to inform this choice. To fill this gap, we will conduct a network meta-analysis (NMA), integrating direct and indirect comparisons from randomized controlled trials (RCTs) to rank antipsychotics according to their effect on cognitive functioning. METHODS: In our NMA, we will include RCTs in patients with schizophrenia or schizophrenia-like psychoses comparing one antipsychotic agent with another antipsychotic agent or placebo that measures cognitive function. We will include studies on patients of every age group, in any phase of illness (e.g., acute or stable, first episode or chronic schizophrenia, in- or outpatients) with an intervention time of at least 3 weeks. The primary outcome will be the composite score of cognitive functioning, preferentially measured with the test battery developed by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative. The secondary outcomes include the seven cognitive domains that the composite score is composed of, as well as functioning and quality of life. Study selection and data extraction will be cond...